# US 2013/0158676 A1 · Flowable tissue products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158676 A1
- Document ID: US20130158676A1
- Status: Published application
- Kind: A1
- Application number: 13/717,808
- Filed: 2012-12-18
- Published: 2013-06-20
- Earliest claimed: 2011-12-20
- Assignees: LifeCell Corporation
- Inventors: Mark Hayzlett; Ivis Munoz; Nimesh Kabaria; Joshua Czeczuga
- Web page: https://patentgrep.com/patent/US20130158676A1

## CPC

- A61F 2/02: Prostheses implantable into the body
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/3612: {Cartilage, synovial fluid}
- A61L 27/362: {Skin, e.g. dermal papillae}
- A61L 27/3625: {Vascular tissue, e.g. heart valves}
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/34: for soft tissue reconstruction
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection.

## Claims

### Claim 1

A tissue product, comprising:
a plurality of dry tissue matrix particles comprising a longest dimension between about 1 mm and 5 mm, wherein the tissue matrix particles each comprise a plurality of tissue matrix fragments having a length between about 5 μm and 300 μm, and wherein the tissue matrix fragments are formed into the tissue matrix particles.

### Claim 2 (depends on 1)

The tissue product of claim 1, wherein forming the fragments into particles includes joining the fragments without use of a binder or adhesive.

### Claim 3 (depends on 2)

The tissue product of claim 2, wherein the fragments are joined by convective drying.

### Claim 4 (depends on 1)

The tissue product of claim 1, wherein the tissue fragments are cross-linked to one another.

### Claim 5 (depends on 1)

The tissue product of claim 1, wherein the tissue particles each have a length between about 2 mm and 3 mm.

### Claim 6 (depends on 4)

The tissue product of claim 4, wherein the tissue fragments are cross-linked to one another using a dehydrothermal crosslinking process.

### Claim 7 (depends on 1)

The tissue product of claim 1, wherein the particles are substantially spherical.

### Claim 8 (depends on 1)

The tissue product of claim 1, wherein the particles swell when contacted with water.

### Claim 9 (depends on 1)

The tissue product of claims 1, wherein the particles are flowable when dry.

### Claim 10 (depends on 1)

The tissue product of claim 1, wherein the particles form a porous structure with open channels between each of the particles that can support cellular ingrowth and vascularization.

### Claim 11 (depends on 1)

The tissue product of claim 1, wherein the tissue fragments are elongated strands of tissue matrix.

### Claim 12 (depends on 1)

The tissue product of claim 1, wherein the tissue matrix particles are dermal tissue matrix.

### Claim 13 (depends on 1)

The tissue product of claim 1, wherein the tissue matrix particles are porcine tissue matrix particles.

### Claim 14 (depends on 1)

The tissue product of claim 1, wherein the tissue matrix is an acellular tissue matrix.

### Claim 15

A method for producing a tissue composition, comprising:
selecting a tissue matrix;
treating the tissue matrix to produce fragments having a length between about 5 μm and 300 μm;
forming the fragments into particles having a longest dimension between about 1 mm and about 5 mm.

### Claim 16 (depends on 15)

The method of claim 15, further comprising drying the particles to form a plurality of dry particles.

### Claim 17 (depends on 15)

The method of claim 15, wherein drying the particles includes subjecting the particles to a convective drying process.

### Claim 18 (depends on 15)

The method of claim 15, further including treating the particles with a dehydrothermal treatment process.

### Claim 19 (depends on 15)

The method of claim 15, wherein forming the fragments into a plurality of particles includes compressing groups of the fragments.

### Claim 20 (depends on 15)

The method of claim 15, wherein forming the fragments into a plurality of particles includes placing small groups of the fragments in a cold environment to freeze the groups.

### Claim 21 (depends on 20)

The method of claim 20, wherein placing small groups of the fragments in a cold environment to freeze the groups includes extruding the small groups into a cryogenic liquid.

### Claim 22 (depends on 15)

The method of claim 15, wherein the plurality of particles includes substantially spherical particles.

### Claim 23 (depends on 15)

The method of claim 15, wherein treating the tissue matrix to produce fragments includes milling the tissue matrix.

### Claim 24 (depends on 15)

The method of claim 15, wherein the fragments are strands of tissue matrix.

### Claim 25 (depends on 15)

The method of claim 15, wherein the tissue matrix is dermal tissue matrix.

### Claim 26 (depends on 15)

The method of claim 15, wherein the tissue matrix is porcine tissue matrix.

### Claim 27 (depends on 15)

The method of claim 15, wherein the particles are flowable.

### Claim 28 (depends on 15)

The method of claim 15, wherein the tissue matrix is an acellular tissue matrix.
